Axsome Therapeutics Inc
$ 184.18
3.28%
14 Apr - close price
- Market Cap 9,122,166,000 USD
- Current Price $ 184.18
- High / Low $ 184.22 / 178.33
- Stock P/E N/A
- Book Value 1.74
- EPS -3.67
- Next Earning Report 2026-05-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.17 %
- ROE -2.52 %
- 52 Week High 191.50
- 52 Week Low 96.09
About
Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United States. The company is headquartered in New York, New York.
Analyst Target Price
$223.99
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-23 | 2025-11-03 | 2025-08-04 | 2025-05-05 | 2025-02-18 | 2024-11-12 | 2024-08-05 | 2024-05-06 | 2024-02-20 | 2023-11-06 | 2023-08-07 | 2023-05-08 |
| Reported EPS | -0.56 | -0.95 | -0.97 | -1.2157 | -1.54 | -1.3419 | -1.67 | -1.44 | -2.08 | -1.32 | -1.54 | -0.26 |
| Estimated EPS | -0.7256 | -0.85 | -1.06 | -1.21 | -1.0026 | -1.41 | -1.33 | -1.2 | -1.17 | -1.2 | -1.22 | -1.04 |
| Surprise | 0.1656 | -0.1 | 0.09 | -0.0057 | -0.5374 | 0.0681 | -0.34 | -0.24 | -0.91 | -0.12 | -0.32 | 0.78 |
| Surprise Percentage | 22.8225% | -11.7647% | 8.4906% | -0.4711% | -53.6006% | 4.8298% | -25.5639% | -20% | -77.7778% | -10% | -26.2295% | 75% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-04 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.8 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AXSM
2026-04-13 13:09:27
This article examines Axsome Therapeutics (AXSM) valuation amidst its upcoming FDA decision for Auvelity, a central nervous system disorder treatment. While the stock has seen significant returns over the past year, analysts suggest it's undervalued. The article highlights potential for diversified revenue and discusses differing valuation models, including Simply Wall St's DCF analysis.
2026-04-13 09:40:25
Iridian Asset Management LLC CT has reduced its stake in Axsome Therapeutics, Inc. by 11.7%, selling 9,770 shares, though it remains its 8th largest holding. The biopharmaceutical company reported strong Q4 operational results, beating EPS estimates and growing revenue by 65% year-over-year. Despite institutional ownership of 81.49% and an average analyst rating of "Moderate Buy," insiders have also sold a significant number of shares recently.
2026-04-11 10:21:00
UBS has increased its price target for Axsome Therapeutics (NASDAQ:AXSM) to $259 from $251, maintaining a Buy rating. The adjustment is based on the company's central nervous system growth platform and the anticipated regulatory decision for Auvelity's atypical depression application, with an April 30 PDUFA date. UBS anticipates an earlier approval and estimates an additional $2 billion in sales from this new indication.
2026-04-11 01:09:03
This page on Stock Titan provides comprehensive access to Axsome Therapeutics (AXSM) SEC historical filings, including 10-K annual reports, 10-Q quarterly reports, and 8-K material events. It highlights how these documents communicate financial results, product revenue, and pipeline updates for CNS conditions. The article also features recent insider transaction details and proposed sales for AXSM directors, along with AI-powered summaries of these filings.
2026-04-10 21:40:17
Axsome Therapeutics (AXSM) saw a 6.2% stock increase following its announcement of first-quarter 2026 results and an upcoming FDA decision on Auvelity for Alzheimer's agitation. Analysts anticipate this new indication could be a significant revenue stream, considering the high unmet medical need and the drug's existing antidepressant classification potentially avoiding an added mortality boxed warning. The FDA ruling is a key near-term catalyst that could impact Axsome’s revenue mix, cash burn, and reliance on its core products.
2026-04-10 16:40:17
UBS Group has increased its price target for Axsome Therapeutics (NASDAQ:AXSM) to $259, maintaining a "buy" rating and suggesting a significant upside. Other analysts have also raised their price targets, contributing to a "Moderate Buy" consensus. Despite positive revenue growth and beating EPS estimates, the company remains unprofitable, and recent insider sales have been noted.
